Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Bioverativ

- PMLiVE

Dupixent bounce-back helps stem diabetes declines at Sanofi

CEO Brandicourt says Sanofi will “enter a new growth phase”

Biogen Idec building

Big debate follows Biogen/Eisai’s Alzheimer’s study unveiling

Mixed results prompted a 10% share drop for both companies

- PMLiVE

Spinraza keeps Biogen buoyant ahead of Alzheimer’s data

Biotech sees 9% growth ahead of potential landmark announcement

- PMLiVE

Ashfield and Sanofi scoop ICE award

Company wins the Most Effective Agency Collaboration Award for the second year running

Biogen Idec building

Biogen and Eisai claim mid-stage win for Alzheimer’s drug

Says drug slowed down progression of cognitive decline

- PMLiVE

Sanofi’s rare blood disorder drug Cablivi set for European approval

Rare disease drug among notable CHMP recommendations

- PMLiVE

Commentary: Roseanne’s racist tweet and Sanofi’s swift and surprising riposte

Alexander Davies considers the remarkable story of how one company broke with pharma convention to speak out on social media

Sanofi reception

Sanofi poaches Peugeot’s finance head

Jean-Baptiste Chasseloup de Chatillon joins the French drugmaker as chief financial officer

- PMLiVE

Evotec says Sanofi deal makes it anti-infectives powerhouse

Aims to inject biotech nimbleness into anti-infectives portfolio

- PMLiVE

Biogen appoints executive VP, corporate development

Daniel Karp will also become a member of the executive committee

- PMLiVE

Roche’s MabThera ends drug drought for serious skin disease

As biosimilars seize market share, Roche finds ways to extend blockbuster's revenues

- PMLiVE

Drugs for rare diseases will help propel pharma sales to $1.2trn by 2024; report

Orphan drug sales growth will be 11%+ a year

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links